<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">Lung metastases</z:e> are considered a poor prognostic factor in patients with resectable colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>STUDY DESIGN: We reviewed records of 1,260 consecutive patients with liver-only or liver-plus-lung (L+L) <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> who underwent resection with curative intent (1995 to 2009) </plain></SENT>
<SENT sid="2" pm="."><plain>Survival and prognostic factors were analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: There were 112 patients who underwent resection of L+L (mean 2 liver, 2 lung <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>Mean <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> sizes were 3 cm and 1 cm, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Thirty-four (31%) had bilateral <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Ten (9%) had synchronous L+L <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, 60 (54%) had diagnosis of <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e> within 1 year of liver resection </plain></SENT>
<SENT sid="7" pm="."><plain>Most (108 of 112, 96%) had resection of liver before or at the same time as lung </plain></SENT>
<SENT sid="8" pm="."><plain>Preoperative chemotherapy was used in 77 (69%) before liver resection and 56 (50%) before lung resection </plain></SENT>
<SENT sid="9" pm="."><plain>Among L+L patients, no postoperative <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred; postoperative morbidity rates were 26% after liver resection and 4% after lung resection </plain></SENT>
<SENT sid="10" pm="."><plain>After a median of 49 months follow-up, L+L patients (n = 112) had better survival than liver only (n = 1,148) (5-year overall survival, L+L, 50% vs liver only, 40%; p = 0.01) </plain></SENT>
<SENT sid="11" pm="."><plain>CEA level &gt; 5 ng/dL (hazard ratio [HR] 2.1, 95% CI 1.1 to 4.4, p = 0.04) and rectal primary (HR 2.9, 95% CI 1.4 to 6, p = 0.004) were associated with worse survival in L+L patients </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: The survival rate for patients who undergo resection of L+L <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is greater than the survival rate of the general population of patients who undergo resection of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> only </plain></SENT>
<SENT sid="13" pm="."><plain>The presence of resectable <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e> is neither a poor prognostic factor nor a contraindication to resection of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
</text></document>